Edwards acquires Baxter JV
This article was originally published in The Gray Sheet
Japanese cardiovascular business purchase for $22 mil. will contribute to the firm's growing global presence, Edwards says Oct. 1. The purchase price excludes $30 mil. in receivable securitized accounts. The business unit, operating as a joint venture with Baxter International, generated sales of $170 mil. in 2001. Edwards Lifesciences will record approximately $3 mil. in one-time expenses from the acquisition in the third quarter...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.